Adaptive Phage Therapeutics announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision phage therapy in patients with Diabetic Foot Osteomyelitis.
Preprint: Gram-positive bacteria evade phage predation through endolysin-mediated L-form conversion. Read author Martin Loessner’s Twitter thread on this report!
Opinion: Diversity in the soil virosphere: to infinity and beyond? Read author Simon Roux’s Twitter thread on this report!
Paper: Phage-mimicking nanoagents for rapid depolymerase specificity screening against multidrug resistant bacteria.
News article: Rediscovering phages: ‘We finally have the tools to harness them’.